Endocarditis bacterial – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 03 Aug 2026 10:45:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Endocarditis bacterial – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Dalbavancin versus standard drug combination for treatment of infective endocarditis caused by Gram‑positive cocci in adult patients https://clinicaltrials.eu/trial/dalbavancin-versus-standard-drug-combination-for-treatment-of-infective-endocarditis-caused-by-gram-positive-cocci-in-adult-patients/ Mon, 03 Aug 2026 10:45:47 +0000 https://clinicaltrials.eu/trial/dalbavancin-versus-standard-drug-combination-for-treatment-of-infective-endocarditis-caused-by-gram-positive-cocci-in-adult-patients/ The study focuses on adults with infective endocarditis, an infection of the heart’s inner lining, that is caused by Gram‑positive cocci – a group of round‑shaped bacteria such as staphylococci, streptococci and enterococci. The investigational medication is dalbavancin, which is given by a single intravenous (IV) infusion, and it is being compared with the usual standard antibiotic therapy that typically includes drugs like vancomycin given through an IV line and may later be changed to oral antibiotics. The purpose of the study is to determine whether treatment with dalbavancin improves treatment success at day 90 compared with standard therapy.

Participants who meet the study criteria are randomly assigned to receive either the single‑dose dalbavancin infusion or the conventional antibiotic regimen. After the initial treatment, patients remain in the hospital for monitoring and then are discharged with scheduled follow‑up visits to check for any heart complications, repeat infections, or the need for heart surgery. Follow‑up assessments are performed at several time points up to 90 days (and later at one year) and include simple health questionnaires and basic examinations to evaluate recovery and any side effects. Throughout the study, safety checks are made to ensure the medication is well tolerated.

]]> Study Comparing Oral Amoxicillin to Outpatient IV Antibiotics for Patients with Infective Endocarditis https://clinicaltrials.eu/trial/study-comparing-oral-amoxicillin-to-outpatient-iv-antibiotics-for-patients-with-infective-endocarditis/ Mon, 03 Aug 2026 10:33:51 +0000 https://clinicaltrials.eu/trial/study-comparing-oral-amoxicillin-to-outpatient-iv-antibiotics-for-patients-with-infective-endocarditis/ This clinical trial is focused on studying a condition known as infective endocarditis, which is an infection of the inner lining of the heart chambers and valves. The study is comparing two different ways of treating this infection: using oral antibiotics and using antibiotics given through a vein, known as parenteral treatment. The oral antibiotic being used in this study is amoxicillin, which is a common medication used to treat various bacterial infections.

The purpose of the study is to see if taking antibiotics by mouth is as effective as receiving them through a vein for treating infective endocarditis. Participants in the study will receive either the oral antibiotic or the parenteral antibiotic treatment. The study will monitor participants over a period of time to observe any differences in outcomes such as hospitalizations, the need for additional heart surgery, or the recurrence of the infection.

Throughout the study, researchers will also look at the quality of life and satisfaction of the participants, as well as the costs associated with each type of treatment. This will help determine if one method is more beneficial overall. The study aims to provide valuable information on the best way to treat infective endocarditis, potentially improving care for future patients with this condition.

]]>